Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab - 12/08/11
Doi : 10.1016/j.jaad.2006.08.025
Akmal S. Hassan, MD, Ursula Kaelin, MD, Lasse Roger Braathen, MD, PhD, Nikhil Yawalkar, MD ⁎ 
From the Department of Dermatology, University of Bern, Inselspital
Reprint requests: Nikhil Yawalkar, MD, Department of Dermatology, University of Bern, Inselspital, 3010 Bern, Switzerland.Bern, Switzerland
Abstract |
Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.
Le texte complet de cet article est disponible en PDF.Plan
| Serono Pharma Switzerland provided efalizumab. Disclosure: Dr Braathen has served as a consultant to Biogen, Essex, Wyeth Pharmaceuticals, and Serono. Dr Yawalkar has served as a consultant to Biogen, Wyeth Pharmaceuticals, and Serono. Dr Yawalkar has received research trial support from Biogen and Serono. Drs Hassan and Kaelin have no conflicts of interest to disclose. |
© 2007
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 56 - N° 2
P. 217-221 - février 2007 Retour au numéro
Article précédent
- Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis
- Jennifer Krejci-Manwaring, Mark G. Tusa, Christie Carroll, Fabian Camacho, Mandeep Kaur, David Carr, Alan B. Fleischer, Rajesh Balkrishnan, Steven R. Feldman
- Efalizumab for severe atopic dermatitis: A pilot study in adults
- Rodd Takiguchi, Susan Tofte, Brenda Simpson, Erin Harper, Andrew Blauvelt, Jon Hanifin, Eric Simpson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?